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Introduction: Antiretroviral pre-exposure prophylaxis (PrEP) for
the prevention of HIV acquisition is cost-effective when delivered to
those at substantial risk. Despite a high incidence of HIV infection
among pregnant and breastfeeding women in sub-Saharan Africa
(SSA), a theoretical increased risk of preterm birth on PrEP could
outweigh the HIV prevention benefit.
Methods:Wedeveloped a decision analytic model to evaluate a strategy
of daily oral PrEP during pregnancy and breastfeeding in SSA. We
approached the analysis from a health care system perspective across
a lifetime time horizon. Model inputs were derived from existing literature
and local sources. The incremental cost-effectiveness ratio (ICER) of PrEP
versus no PrEP was calculated in 2015 U.S. dollars per disability-adjusted
life year (DALY) averted. We evaluated the effect of uncertainty in
baseline estimates through one-way and probabilistic sensitivity analyses.
Results: PrEP administered to pregnant and breastfeeding women
in SSA was cost-effective. In a base case of 10,000 women, the
administration of PrEP averted 381 HIV infections but resulted in
779 more preterm births. PrEP was more costly per person ($450
versus $117), but resulted in fewer disability-adjusted life years
(DALYs) (3.15 versus 3.49). The incremental cost-effectiveness
ratio of $965/DALY averted was below the recommended regional
threshold for cost-effectiveness of $6462/DALY. Probabilistic
sensitivity analyses demonstrated robustness of the model.
Conclusions: Providing PrEP to pregnant and breastfeeding
women in SSA is likely cost-effective, although more data are
needed about adherence and safety. For populations at high risk of
HIV acquisition, PrEP may be considered as part of a broader
combination HIV prevention strategy.
Key Words: pre-exposure prophylaxis, HIV prevention, pregnancy,
breastfeeding, sub-Saharan Africa, cost-effectiveness
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INTRODUCTION
Antiretroviral (ARV) pre-exposure prophylaxis (PrEP)
has been shown to prevent HIV acquisition among at-risk
individuals. Daily oral tenofovir–emtricitabine (TDF-FTC)
reduced up to 70% of incident HIV infections among
heterosexual couples, intravenous drug users, and men who
have sex with men.1–4 Although some clinical trials of PrEP
use among women have shown equivocal results, these
findings were likely due to variable adherence observed among
study participants.5–7 With demonstrated feasibility and accept-
ability of PrEP in early pilot programs,8–10 the scale-up of PrEP
in HIV prevention initiatives has been supported broadly by the
World Health Organization (WHO), the U.S. Centers for
Disease Control and Prevention, and others.11–13
Previous analyses have shown PrEP to be cost-effective
when delivered to populations at highest risk of HIV infec-
tion.14–16 HIV incidence among young women in sub-Saharan
Africa (SSA) is one of the highest in the world.17 Rates of HIV
acquisition in this population may double during pregnancy and
breastfeeding, and the risk of consequent mother-to-child
transmission (MTCT) is tripled when incident maternal infec-
tion occurs during this period.18,19 Despite a clear need for
primary HIV prevention in this at-risk population, there remains
incomplete evidence on the safety and effectiveness of TDF-
FTC use by HIV-uninfected women during pregnancy and
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breastfeeding.11,20,21 Some triple-drug HIV treatment regimens
have been associated with an increased risk of preterm birth
(PTB) and other adverse outcomes, although the contribution of
specific ARV drugs is unclear.22–27 A potential increase in PTB
risk due to ARV drug exposure, coupled with low adherence
and effectiveness, could negate any HIV prevention benefit of
PrEP in this population. To better understand the role of HIV
prophylaxis during this period of heightened risk, we conducted
a cost-effectiveness analysis of oral PrEP among pregnant and
breastfeeding women in SSA. An economic modeling analysis
can help to identify current knowledge gaps in PrEP imple-
mentation research and inform policy decisions regionally
and internationally.
METHODS
Economic Model, Setting, and
Population Characteristics
We constructed a decision analytic model to compare the
costs and effectiveness of the reference strategy of no PrEP
against a scenario of PrEP provision to pregnant and breastfeed-
ing women in SSA (TreeAge Pro, Williamstown, MA; Supple-
mental Fig. 1, http://links.lww.com/QAI/A829). We considered
a lifetime time horizon and approached the analysis from the
perspective of the health care system. Costs and utilities were
discounted at a 3% annual rate.28 The primary outcome measure
was the incremental cost-effectiveness ratio (ICER), measured as
2015 U.S. dollars (USD) per disability-adjusted life years
(DALYs) averted. Cost-effectiveness was defined according to
WHO guidelines as an ICER ,3 times the per capita gross
domestic product (GDP); a very cost-effective intervention
requires an ICER less than the per capita GDP.28 The WHO
Afro-E region of SSA (http://www.who.int/healthinfo/statistics/
gbdestimatesregionallist.xls) has an overall per capita GDP of
$2154, which translates to a cost-effectiveness threshold of
$6462/DALY averted.28
Our study population was composed of HIV-negative
pregnant and breastfeeding women presenting to antenatal care
(ANC).30,31 We searched the medical literature, conference
abstracts, and published reports to identify setting-specific
estimates for model parameters (Table 1). Where such data were
unavailable or of a narrow scope, we drew estimates from our
HIV care and treatment program in Zambia47 and expert opinion.
Probabilities were calculated from rates using the standard
equation P = 1 2 e2rt. We derived probabilities of HIV
infection from incidence rates in pregnancy (4.7 per 100 person-
years) and postpartum (2.9 per 100 person-years) reported by
a meta-analysis of studies in SSA.18 The MTCT risk if maternal
HIV infection occurs during pregnancy or breastfeeding is
22.7%.18 For women who were infected with HIV in pregnancy
but do not transmit HIV to their fetus, the MTCT risk during
breastfeeding (assuming a median breastfeeding duration of 18
months) was assumed to be similar to that among women with
chronic HIV, or 9%.43 The baseline PTB risk in SSA is 12%;45
HIV infection confers a risk ratio of PTB of 1.5, which is
comparable with the PTB risk in our HIV-infected Zambian
cohort.46,47 The risk of PTB among women taking PrEP is
theoretical and for this analysis was inferred from a randomized
trial comparing the efficacy and safety of triple ARV regimens
for the prevention of MTCT among HIV-infected women, and
was also consistent with data from Zambia.22
Programmatic Assumptions
We assumed that once-daily oral PrEP medication
consisting of TDF-FTC would begin at the first ANC visit with
TABLE 1. Model Parameters
Description Estimate Reference
Baseline characteristics
Median age of pregnancy 24 30,31
Life expectancy adult woman 60 32
Life expectancy HIV+ adult woman 48 31,33
HIV incidence in pregnancy, per 100py 4.7 18
HIV incidence postpartum, per 100py 2.9 18
Disability weight HIV 0.135 34
Cost of HIV/AIDS care (includes ART), $ per py $1300 35,36
Infant/child outcomes
Life expectancy for HIV2 infant 57 32
ART coverage HIV+ adult women 0.43 17,32
ART coverage HIV+ infants/children 0.34 17,32
Life expectancy HIV+ infant, on ART 37 37
Life expectancy HIV+ infant infected peripartum,
no ART
1.1 38
Life expectancy HIV+ infant infected during BF,
no ART
9.4 38
Probability neonatal death, term infant 0.013 39
Probability neonatal death, preterm infant 0.056 39
Mortality at 24 mo, HIV-negative exposed infant 0.08 40–42
Mortality at 24 mo, HIV-negative unexposed infant 0.02 40–42
MTCT risk if incident infection during pregnancy/
BF, %
22.7 18
MTCT risk during BF if infected in pregnancy, % 9 18,43
Disability weight PTB 0.106 44
Baseline PTB risk, % 12 45
PTB risk if maternal HIV infection, % 18 26,46
PTB risk on PrEP, % 20 22,47
Immediate cost of PTB, $ per LBW infant $572 48,49
PrEP administration and monitoring
PrEP effectiveness 0.55 50
Median duration in ANC, wk 20 31
Proportion breastfeeding 0.96 51
Median duration breastfeeding, yrs 1.25 51–53
Cost of PrEP medication (TDF-FTC), $ per py $75 54
Cost of toxicity monitoring and HIV/HepB testing,
$ per py
$140 55
Cost of adherence counseling and monitoring,
$ per py
$100 56
Discounting rate per year, % 3.00 28
GDP per capita, WHO AfroE region $2154* 28,29
All costs are reported in 2015 USD unless otherwise noted.
*Reported in 2005 International dollars.
BF, breastfeeding; HepB, hepatitis B; ART, antiretroviral therapy; MTCT, mother-
to-child transmission of HIV; PTB, preterm birth; PrEP, pre-exposure HIV prophylaxis;
TDF-FTC, tenofovir-emtricitabine; ANC, antenatal care; GDP, gross domestic product.
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a negative HIV screening test and terminate with cessation of
breastfeeding (median 15 months postpartum).51–53 We derived
the median gestational age (GA) of entry into ANC as 19 weeks
and the median GA at delivery as 39 weeks from an
international database.31 We assumed uniform effectiveness of
PrEP for each woman in the base-case analysis, based on
a median time spent in ANC of 20 weeks (ie, 39-week GA at
delivery minus 19-week GA at entry into ANC). Because there
has been no observational study of PrEP in pregnancy, we
varied widely the estimate for effectiveness of PrEP during
pregnancy and breastfeeding to account for variable adherence
and exposure duration. We focused on the index pregnancy only
(and assumed no subsequent pregnancies occurred) and did not
consider the cost or disability of subsequent transmissions
beyond mother and child (eg, to sexual partners). For women
who were infected with HIV during pregnancy or breastfeeding,
we assumed initiation of lifelong antiretroviral therapy (ART)
under recent WHO guidelines for a realistic proportion of
women (43%).11,17 Although current guidelines recommend that
all infants are started on ART as soon as they are diagnosed with
HIV, true coverage of pediatric HIV treatment approximates
34%.11,17,32 We assumed this “real world” coverage rate in our
model to account for infants who fail to access timely health
services and die before diagnosis or treatment.
Cost Parameters
Cost parameters were derived from international eco-
nomic sources and previous cost analyses (Table 1). Where
available, we used relevant purchasing power parity to convert
original costs in local currency to international dollars and then
inflated to 2015 USD. Given that many aspects of HIV
prevention programs are paid for in USD through international
funding agencies, if costs were reported in the literature only in
USD with no reference to original local currency, we directly
inflated these costs to 2015 USD using historical consumer
price index data from the National Bureau of Labor Statistics.57
The cost of PrEP medication for the duration of
pregnancy and breastfeeding was estimated from the cost of
TDF-FTC negotiated by the Clinton Health Access Initiative in
its list of ceiling prices.54 The cost of toxicity surveillance,
based on the recommended quarterly basic metabolic panel
plus HIV and hepatitis B testing,11 was micro-costed from
previous economic analyses in SSA.15,55 We estimated addi-
tional PrEP program costs to include personnel and facility
expenses required for adherence counseling and monitoring
activities based on data from previous economic evaluations of
voluntary counseling and testing strategies.56 Our composite
program cost is higher than that reported by a recent analysis of
PrEP for serodiscordant couples in Uganda; however, given
likely broad regional variations in cost, we intentionally chose
the higher estimates of programmatic costs for our model
inputs.58 The annual cost of care for HIV/AIDS, including
provision of ARVs, was derived from an analysis of costs of
government programs in 45 sites in Zambia35 and is consistent
with ranges reported in previous analyses.36,59,60 The average
cost of PTB per infant was based on two studies in SSA that
reported the cost of care for neonates with low birth weight as
a proxy for prematurity given imprecise GA estimates.48,49 The
cost of PTB was assumed to be a uniform upfront cost and was
not discounted.
Payoff Measures
The primary payoff was calculated in DALY as the sum
of years of life lost (YLL) and years lived with disability
(YLD). We calculated YLD associated with both mother and
infant outcomes using disability estimates from the Global
Burden of Disease Study.34 We used the disability weight for
HIV over the entire life expectancy of an HIV-positive
woman or infant. Disability due to PTB was applied to the
lifetime of all infants born prematurely; for preterm HIV-
positive infants, we used the more severe disability weight
associated with HIV to generate YLD.61
We modeled known differences in neonatal mortality
between term and preterm infants.39 We accounted for differ-
ences in survival between HIV-negative infants born to
infected mothers and those born to uninfected mothers by
modeling differential mortality risk at 24 months of age based
on HIV exposure.40–42 Data are scarce on long-term survival of
HIV-infected children who initiate ART in infancy62; therefore,
we modeled childhood mortality based on a previously
published simulation of the effect of ART on pediatric HIV
disease progression in South Africa63 and subsequently
estimated life expectancy of surviving adolescents from
a Ugandan cohort.37 For HIV-positive infants not receiving
treatment, we modeled life expectancies based on known
survival differences between infants infected in utero or
peripartum versus those infected postpartum.38
Discounting for DALY payoffs in YLL and YLD for
mother and infant was performed using the following
standard equations, where N is number of deaths, r is annual
discount rate (eg, 3%), I is number of incident cases, DW is
disability weight, and L represents years of either standard life
expectancy at age of death (in YLL equation) or duration of
disability (in YLD equation).44
YLL ¼ N
0:03

12 e2 0:003L

YLD ¼ I ·DW ·

12 e2 0:03L

0:03
Cost-Effectiveness and Sensitivity Analyses
Baseline values for cost, utility, and expected survival
for the PrEP scenario were used for the base-case analysis
(Table 1). The ICER, our primary outcome measure, was
defined as the incremental cost (in 2015 USD) per number of
DALYs between a scenario of PrEP provision in pregnancy
and breastfeeding versus the standard scenario of no PrEP.
We performed one-way deterministic sensitivity analyses
of parameters that influenced the ICER outcome using ranges
of best- and worst-case scenarios, derived from previous
clinical trials, meta-analyses, or reasonable assumption. In
one-way sensitivity analyses, costs were varied by a factor of at
least three times the base value to account for uncertainty in
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estimates and assumed wide regional variations. Probabilities
were varied according to ranges from the medical literature or
to account for uncertainty in point estimates and regional
variation. We performed threshold analyses to understand at
which point the value of key uncertain parameters rendered
PrEP not cost-effective. We determined the thresholds of PrEP
effectiveness and the probability of PTB on PrEP, as the
estimates for these variables were most uncertain. We
conducted probabilistic sensitivity analysis (PSA) using Monte
Carlo simulation to assess the confidence in our ICER outcome
by varying all parameters simultaneously over distributions
informed by parameter ranges reported in the literature
at a minimum.
RESULTS
Base Case
In a base-case scenario of 10,000 HIV-negative preg-
nant women in SSA, the administration of daily oral PrEP
through pregnancy and breastfeeding prevented 381 total HIV
infections (485 with PrEP and 866 without PrEP); 303
maternal infections (389 with PrEP and 692 without PrEP)
and 78 infant infections (96 with PrEP and 174 without PrEP)
were averted. PrEP provision was associated with 779
additional PTBs (2000 with PrEP and 1221 without PrEP)
than the no PrEP strategy and an associated 35 more neonatal
deaths (218 with PrEP and 183 without PrEP).
Incremental Costs and Utilities
For the base-case analysis, the PrEP scenario costs an
average of $333 more per person than no PrEP ($450 versus
$117). PrEP provision yielded an average 3.15 DALY
compared with 3.49 DALY in the no PrEP scenario. This
produced an ICER of $965 per DALY averted in the PrEP
scenario. This ICER was much lower than the threshold for
cost-effectiveness of $6462 for the region and even met the
threshold of “very cost-effective,” which is equal to the
regional per capita GDP ($2154/DALY).28
Sensitivity Analyses
One-way deterministic sensitivity analyses showed that
the model was most sensitive to variation in PrEP effectiveness
and probability of PTB while taking PrEP (Table 2). Analyses of
the remaining variables demonstrated confidence in the outcome;
the PrEP strategy remained cost-effective even when varying all
other variables to their highest and lowest range values.
To determine individual thresholds for cost-effectiveness
of key parameters, one parameter was varied widely while all
others were kept stable. Threshold analyses revealed that the
threshold for PrEP effectiveness was 0.78 (ie, a risk ratio for
HIV infection of 0.78 or lower among PrEP users), above
which PrEP lost cost-effectiveness. The probability of PTB on
PrEP at which PrEP was no longer cost-effective was 0.30.
PSAs were performed using Monte Carlo simulation by
1000 iterations; these PSA substantiated the relative robustness
of the model (Fig. 1). Distributions for PSA were derived from
confidence intervals presented in the literature, where available,
or calculated from reasonable assumption of standard devia-
tions. Each cost distribution was set to the range used in one-
way analyses (a factor of at least 3 times the baseline input) and
assigned gamma distribution.64 A gamma distribution was
applied given its constraints to be positive and fully continu-
ous. Both probability and disability distributions were set to
a factor of at least 2 times the baseline input and assigned beta
distributions, bounded at 0 and 1.64 The PrEP strategy was
cost-effective (with an ICER below the willingness-to-pay
threshold of $6462/DALY averted) in 88% of the iterations.
Four percent of the simulations were above the willingness-to-
pay threshold and 8% were dominated (in which PrEP was
both more costly and less effective than no PrEP). The cost-
effectiveness by willingness-to-pay curve demonstrates that the
PrEP strategy was very cost-effective, with an ICER of $2154
or less, in approximately 79% of strategies (Supplemental
Fig. 2, http://links.lww.com/QAI/A829).
DISCUSSION
Daily oral PrEP for the prevention of HIV among
pregnant and breastfeeding women in SSA is likely cost-
effective. Despite upfront programmatic and drug costs, as
well as a modeled elevation in PTB risk, the PrEP strategy
was cost-effective relative to the no PrEP strategy due to the
cost and disability of averted maternal and infant HIV
infections. The ICER outcome was less than internationally
accepted willingness-to-pay thresholds; moreover, the PrEP
strategy met the WHO definition of very cost-effective and
likely remains cost-effective even in those countries where
per capita productivity is lower than in the region overall.28
Previous analyses in other high-risk groups such as men
who have sex with men, female sex workers, intravenous
drug users, and serodiscordant couples have shown PrEP to
be cost-effective,15,16,65–67 but rarely cost-saving.14 Multiple
studies on oral and topical PrEP in southern Africa have
reported ICERs of less than $5000 per QALY saved or
DALY averted, with cost-effectiveness driven by adherence
and prioritization of provision to those at highest risk.14–16,58,60
To date, however, cost-effectiveness of PrEP during preg-
nancy and breastfeeding has not been studied. Many addi-
tional factors in this population require consideration,
including medication adherence during pregnancy; maternal,
fetal, and infant toxicities; induced ARV drug resistance; and
the potential for HIV transmission to infants (among women
infected despite prophylaxis).
Our economic model was most sensitive to variation in
PrEP effectiveness, which is highly dependent on medication
adherence.50 In some clinical trials, low adherence among study
participants has rendered PrEP ineffective altogether.5,6,50,68
Adherence to oral and vaginal regimens of PrEP has varied
considerably among nonpregnant women and women with
incident pregnancy.5,69,70 It is possible that low adherence may
be attributed in part to the design of those clinical trials; most
PrEP studies that reported no effect on HIV acquisition among
women have been randomized, blinded placebo-controlled
trials where participants were uncertain about efficacy and
whether or not they received the active agent. In one open-label
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study among women, adherence was noted to be high (up to
76%), particularly among those on once-daily oral dosing.10
Open-label implementation studies offering PrEP to pregnant
and breastfeeding women could optimize PrEP effectiveness, at
relatively low cost per participant, by adherence monitoring
and counseling on the effectiveness of PrEP if taken consis-
tently. Finally, prioritization of PrEP initiation early in
pregnancy would maximize prophylactic exposure and PrEP
TABLE 2. One-way Deterministic Sensitivity Analyses
Parameter
Range
Minimum
Incr
Cost
DALY
Averted
ICER
($/DALY)
Range
Maximum
Incr
Cost
DALY
Averted
ICER
($/DALY)
PrEP effectiveness50 0.30 $322 0.66 485 0.95 $350 20.16 Dominated
Probability of PTB on PrEP22,47 0.10 $276 0.63 438 0.45 $475 20.37 Dominated
Probability of HIV in
pregnancy18
0.01 $342 0.13 2646 0.10 $310 0.89 348
Cost of PrEP program55,56 $80 $176 0.35 509 $720 $804 0.35 2332
Probability of HIV in
breastfeeding18
0.01 $340 0.16 2137 0.05 $329 0.45 732
Cost of PrEP54 $25 $284 0.35 823 $225 $480 0.35 1392
Cost of PTB48,49 $200 $304 0.35 881 $2000 $444 0.35 1287
Each parameter listed was varied according to ranges noted, holding all other parameters constant. Costs and probabilities were varied widely to estimate best- and worst-case
scenarios for each parameter. The order of the parameters in this table reflects the effect of each parameter on the incremental cost-effectiveness ratio (ICER) outcome—parameters at
the top of the table (pre-exposure prophlyaxis (PrEP) effectiveness and probability of preterm birth (PTB) on PrEP) drove the ICER most significantly, whereas variation of parameters
at the bottom affected the ICER less. Varying other parameters not listed did not affect the ICER outcome. ICERs noted to be “dominated” indicate that PrEP was both more expensive
and less effective than no PrEP at that parameter value. Incr cost, incremental cost; DALY, disability-adjusted life year; ICER, incremental cost-effectiveness ratio; PrEP, pre-exposure
HIV prophylaxis; PTB, preterm birth.
FIGURE 1. Probabilistic sensitivity analysis of incremental cost-effectiveness of pre-exposure prophylaxis (PrEP) vs. no PrEP, shown
in a scatter plot. Each point estimate represents one iteration (total 1000) of incremental cost and incremental effectiveness of the
PrEP strategy versus no PrEP, based on the range of parameter distributions. The oval represents the 95% confidence interval of all
1000 iterations. The solid line represents the willingness-to-pay threshold of $6462 per DALY, or 3 times the regional per capita
GDP. Any point to the left of the solid line represents an incremental cost-effectiveness ratio (ICER) above the willingness-to-pay
threshold. Approximately 88% of all estimated ICER iterations demonstrated cost-effectiveness of the PrEP strategy. No points fell
below the horizontal axis and therefore no iterations demonstrated cost savings. Points to the left of the dashed vertical axis (8%
of all iterations) indicate increased cost and less effectiveness of the PrEP strategy (ie, dominance of PrEP by no PrEP).
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effectiveness. Data from future observational studies with
participants enrolled at different GAs of pregnancy will
allow us to determine GA thresholds at which initiating
PrEP is not cost-effective.
Our analysis suggests that the benefits of maternal and
neonatal HIV prevention from PrEP outweigh even a sub-
stantially increased risk of PTB from ARV drug exposure.
This increase in PTB among women taking PrEP is
theoretical. To date, there has been no increase in adverse
pregnancy outcomes observed among pregnant women on
TDF for hepatitis B infection.71 Similarly, PrEP has been
shown to be safe among women who became pregnant while
taking PrEP, although the study drug was discontinued
immediately when pregnancy was diagnosed (at a median
GA of 5 weeks).20 An increased risk of adverse pregnancy
outcomes has been found among HIV-infected women on
certain triple-drug treatment regimens,23,24,26 particularly
those containing protease inhibitors.25,72 Results from the
PROMISE trial demonstrated a risk of PTB of up to 20%
among HIV-positive pregnant women taking combination
ARV regimens to prevent MTCT, which is consistent with
analyses from our own data in Zambia.22,47 Despite our
conservative assumption that PrEP users in our cohort would
experience this same elevated risk of PTB, administration of
PrEP in pregnancy remained cost-effective. The threshold
PTB risk at which PrEP lost cost-effectiveness was quite high
at 30%. If demonstrated in clinical studies, however, this risk
could preclude PrEP from being a viable prevention option
in pregnancy.
The background risk of HIV infection in pregnancy and
breastfeeding drove the ICER only modestly across its range
values (Table 2), suggesting that PrEP may be cost-effective
in areas of even lower HIV incidence. While WHO guidelines
recommend PrEP for populations with HIV incidence of 3 per
100 person-years or higher, the incidence threshold at which
PrEP becomes cost-effective is influenced by the PrEP-ART
cost ratio and PrEP effectiveness.11,13,50 Furthermore, this
incidence threshold is likely lowered in scenarios where PrEP
can reduce the risk of HIV acquisition in more than one
individual (eg, in the mother–infant pair). However, because
the cost-effectiveness of PrEP is closely linked to the broader
HIV epidemic context, we anticipate that as expanding ART
coverage and other prevention efforts reduce HIV incidence
in SSA, modification of this analysis will be necessary.
Among HIV-infected pregnant and breastfeeding
women, the risks of combination ARV regimens on maternal
and fetal outcomes are outweighed by significant benefits to
both mother and child. These risks have not been thoroughly
evaluated in the context of TDF-FTC for HIV prevention
among uninfected pregnant and breastfeeding women. The use
of PrEP has been associated with mild and transient decreases
in renal function that resolve after PrEP discontinuation.5,73,74
Renal toxicity of PrEP regimens may be more severe in
pregnancy, however, during which a physiologic increase in
GFR balances changes in systemic and renal hemodynamics
characterized by marked volume expansion and vasodilation.
Additionally, fetal tenofovir exposure in utero and through
breast milk may be associated with decreased infant
bone mineral content and growth; but longitudinal data are
sparse.21,75–79 Early results from IMPAACT P1084s, a substudy
of PROMISE, showed that use of combination ARV drug
regimens during pregnancy resulted in lower infant
bone mineral content at birth compared with antenatal
zidovudine and intrapartum nevirapine. When tenofovir-
based ART was compared with other combination regimens
in subset analyses, however, no differences were observed.80
Given uncertainty regarding maternal and infant toxicity of
PrEP in pregnancy and breastfeeding—and the evident safety
in nonpregnant populations—we did not consider additional
costs or disability from these potential complications. As new
data emerge from PrEP implementation studies, such assump-
tions may need to be revisited and incorporated into future
cost-effectiveness models.
In studies among PrEP users with incident HIV infec-
tion, ARV drug resistance has been rare and has occurred
primarily when PrEP was initiated in a patient with unrecog-
nized HIV infection.81 In a WHO meta-analysis, the overall
risk of resistance in PrEP studies was reported as 0.1%, much
lower than the background transmitted resistance of nearly 3%
in SSA.11,82 Mathematical modeling has predicted that the
cumulative risk of resistance due to PrEP would be lower than
the risk of resistance associated with treating the HIV
infections that would otherwise occur.83 For these reasons,
we did not estimate additional costs or disability attributable to
ARV drug resistance acquired in the setting of HIV infection
despite prophylaxis. Health care providers should emphasize
HIV testing before initiation of PrEP. Surveillance for resistant
infection is also needed for women and their infants who do
become infected with HIV despite PrEP usage. As new data
emerge in this critical area, particularly from programmatic
settings, our analyses may need to be refined accordingly.
This model has several limitations. First, because no
clinical studies have evaluated the use of PrEP in pregnancy
and breastfeeding, the PrEP effectiveness model parameter was
derived from a pooled analysis of multiple short-term studies
among diverse populations.11,13 “Real world” PrEP effective-
ness can vary substantially based on medication efficacy,
adherence, and timing of initiation, which in turn drive the
cost-effectiveness of program implementation. Second, we
used the disability weight of HIV only and did not account
for additional disability due to AIDS, a conservative approach
that could underestimate the effectiveness of PrEP. Although
the universality of disability weights from the Global Burden
of Disease study has been debated,34,84–86 these weights are
nevertheless recommended by the WHO for analyses in
resource-limited settings.28 Third, we derived a uniform cost
of PTB from two small regional studies that, while consistent,
may not be generalizable to the entire SSA region. The cost of
PTB may differ substantially with advances in resources and
capacity for neonatal intensive care.48,49 Furthermore, the cost
of PTB certainly varies according to GA at delivery, but this
was held constant in our analysis. A more nuanced model
would consider the variance of cost and disability based on
prematurity severity. To accomplish this, however, better data
are required concerning GA distributions and true PTB risk in
the context of PrEP use. Fourth, we assumed lifelong ART for
only a proportion of HIV-infected adult women and infants,
based on current global coverage estimates. Although our
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model outcome was not significantly affected by variation of
individual ART coverage assumptions, expanded ART cover-
age across SSA could reduce the cost-effectiveness of various
prevention strategies including PrEP. Fifth, we did not account
for costs or disabilities of subsequent HIV infections beyond
those described in our current model. Finally, we estimated
costs for drugs, monitoring, and adherence support that in
reality could vary significantly across countries and regions and
depend on external donor funding.
Despite optimistic results from this initial economic
analysis, additional considerations of participant demand,
health education, local affordability, donor funding, and social
equity preferences are crucial components of decision-making
when resources are scarce.87–89 In this analysis, we considered
PrEP as a single intervention; however, there is increasing
evidence that combination strategies hold greatest promise for
primary HIV prevention.90 The scale-up of other HIV pre-
vention strategies in pregnancy, for both women and their
partners, may be comparable or even superior alternatives to
the addition of PrEP alone.14,16,55,58,60 In settings with finite
resources, the opportunity costs of any single prevention
strategy require careful consideration. While this initial model
shows cost-effectiveness over no PrEP, further analysis should
evaluate how PrEP for pregnant and breastfeeding women may
be included in the optimal mix of a multistrategy prevention
program in SSA.89,91
In summary, our analysis suggests that provision of PrEP
for HIV prevention among pregnant and breastfeeding women
in SSA may be cost-effective, even in scenarios of high PTB
risk and modest PrEP effectiveness. Concerns regarding
medication adherence, viral resistance, maternal and fetal
toxicity, and PTB require empirical clarification through
large-scale implementation studies. Based on the existing
evidence—and from a perspective of resource allocation—
PrEP provision to pregnant and breastfeeding women at high
risk of infection could be a promising addition to combination
HIV prevention programs.
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